Boehringer Ingelheim Gene Therapy Collaboration

About HeartBeat.bio

HeartBeat.bio is a TechBio company developing a next-generation platform for cardiac drug discovery based on its proprietary human heart organoids, called Cardioids. These 3D models replicate the architecture and function of human heart chambers, enabling scalable, high-throughput disease modeling and compound screening. The company has secured strategic collaborations with major pharmaceutical and technology partners, such as Boehringer Ingelheim and Molecular Devices, and raised €4.5 million in a Pre-Series A round to scale its platform. Its business model centers on providing a technology platform and research services to accelerate and de-risk drug development for heart failure, cardiomyopathies, and other cardiac conditions.

Therapeutic Areas